Figure 4 | Scientific Reports

Figure 4

From: Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells

Figure 4

Exploration of AToMI results in heterogeneous GB cell lines. (A, B) Viability of T98G (A) and established GB, E98 and U87MG, and patient-derived GSCs, BT3-CD133+ and BT12, cell lines (B) treated with the selected kinase inhibitors alone or in combination with 8 µM NZ-8-061, 6 µM DBK-1154 or 10 µM DBK-766 for 72 h. Human fibroblasts were used as a control of normal cells. Data as mean ± SD (n = 3 independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001 by Student's t-test. Red striped line indicates 50% inhibition of cell viability which is considered as a cytostatic but not cytotoxic response. (C) Heat map representation of quantified colony growth assay data in the indicated established GB cell lines, patient-derived GSCs under vehicle (DMSO) or 8 µM NZ-8-061 (NZ) treatment either alone or in combination with indicated kinase inhibitors. Human fibroblasts used as a control of normal cells. (n = 2 independent experiments).

Back to article page